Two sites (23–30, 76–90) on rat P-selectin mediate thrombin activated platelet-neutrophil interactions

• Published in: Comparative biochemistry and physiology. A, Comparative physiology Vol. 109; no. 4; pp. 881 - 886
• Main Authors: Chignier, E., Sparagano, M.H., Mcgregor, L., Thillier, A., Pellecchia, D., Mcgregor, J.L.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.1994
• Subjects: Platelet-neutrophil interactions; Rat P-selectin; Platelet-neutrophil interactions; Rat P-selectin
• ISSN: 0300-9629
• DOI: 10.1016/0300-9629(94)90235-6

The lectin-like domain of P-selectin, an adhesive receptor (also known as PADGEM, GMP-140 or CD62) is implicated in platelet or endothelial cell interactions with leukocytes. The aim of this study was to characterize the lectin-like domain of rat P-selectin by the use of synthetic peptides. The lectin and EGF-like domains of rat P-selectin were cloned in our laboratory and shown to present very strong homologies to its human counterpart. Peptides corresponding with the lectin-like domain of P-selectin were tested for their ability to inhibit thrombin-activated platelets rosetting to neutrophils. Peptides 23–30 (A) and 76–90 (C), but not peptide 51–61 (B), inhibited thrombin activated rat platelets interactions with rat neutrophils (A = 33%, C = 46%, P < 0.05). Using a combination of peptides (A + B = 35%, P = 0.008 and A + C = 62%, P < 0.001), we observe different degrees of inhibition of platelets binding to neutrophils. The IC 50 of peptides A+C was O.llmM. LYP-20, an anti-human P-selectin monoclonal antibody, was also observed to inhibit thrombin-activated rat platelets binding to rat neutrophils in a very significant manner (57% of inhibition, P < 0.001). Moreover, heparin inhibited thrombin-stimulated platelet/neutrophils rosetting (36% of inhibition, P < 0.01). These results show the importance of two sites (23–30 and 76–90) on the lectin-like domain of P-selectin in mediating platelet-neutrophil interactions in rats. Such peptides may be potent in vivo inhibitors of cell-cell interactions involving P-selectin.